CN Patent

CN101347405A — 一种甲磺酸双氢麦角毒碱注射液的处方及生产工艺

Assigned to Guangzhou Mingguan Pharmaceutical Technology Co Ltd · Expires 2009-01-21 · 17y expired

What this patent protects

本发明公开了一种甲磺酸双氢麦角毒碱注射液的处方和生产工艺，属于医药技术领域。本发明所涉及的甲磺酸双氢麦角毒碱注射液处方由主药甲磺酸双氢麦角毒碱、稳定剂和pH值调节剂组成；生产工艺主要包括配液、过滤、灌装和灭菌四个步骤。并经灭菌工艺验证，加速、长期试验和配伍试验等试验例证实了本发明生产工艺可行，质量稳定。

USPTO Abstract

本发明公开了一种甲磺酸双氢麦角毒碱注射液的处方和生产工艺，属于医药技术领域。本发明所涉及的甲磺酸双氢麦角毒碱注射液处方由主药甲磺酸双氢麦角毒碱、稳定剂和pH值调节剂组成；生产工艺主要包括配液、过滤、灌装和灭菌四个步骤。并经灭菌工艺验证，加速、长期试验和配伍试验等试验例证实了本发明生产工艺可行，质量稳定。

Drugs covered by this patent

dihydroergotamine-mesylate (DIHYDROERGOTAMINE MESYLATE)

Patent Metadata

Patent number: CN101347405A
Jurisdiction: CN
Classification: —
Expires: 2009-01-21
Drug substance claim: No
Drug product claim: No
Assignee: Guangzhou Mingguan Pharmaceutical Technology Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.